GlassScriptPhysician profile
Mark R Vesely
NPI 1689715641
$7,370.10
in general payments reported to CMS, 2019-2025
24 companies · $794 in 2025
The $794 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,990 · 2020: $169 · 2021: $108 · 2022: $378 · 2023: $248 · 2024: $2,683 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876 · Travel and Lodging: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.39 |
| Travel and Lodging | $1,848.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,870.57 | 2019-2024 | |
| Edwards Lifesciences Corporation | $1,598.58 | 2022-2025 | Evoque, Pascal, Sapien 3 Ultra Resilia |
| Medical Device Business Services, INC. | $1,298.39 | 2019 | |
| Medtronic Vascular, INC. | $1,099.04 | 2019-2020 | |
| Medtronic, INC. | $506.76 | 2021-2025 | Symplicity G3 |
| Scpharmaceuticals INC. | $152.42 | 2025 | |
| Intuitive Surgical, INC. | $85.58 | 2023 | Da Vinci Surgical System |
| Pfizer INC. | $84.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.92 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $75.92 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $73.57 | 2019-2025 | Farxiga |
| Esperion Therapeutics, INC. | $64.42 | 2025 | Nexletol |
| Z-Medica, LLC | $57.54 | 2020 | |
| Siemens Medical Solutions USA, INC. | $56.14 | 2023-2024 | Acuson Sc2000 Diagnostic Ultrasound System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.75 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $43.46 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $36.74 | 2025 | |
| Janssen Pharmaceuticals, INC | $31.98 | 2024 | Xarelto |
| Amgen INC. | $24.59 | 2025 | Repatha |
| Inari Medical, INC. | $22.66 | 2022 | |
| Bridgebio Pharma, INC. | $15.89 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $15.74 | 2025 | |
| Glaxosmithkline, LLC. | $13.93 | 2025 | Shingrix, Arexvy |
| Teleflex LLC | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vesely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.